$ 3.43 Billion growth expected in Anaplastic Lymphoma Kinase (ALK) Inhibitors Market | 20.14% YOY growth in 2021 amid COVID-19 Spread | North America to Notice Maximum Growth | Technavio

NEW YORK, May 14, 2021 /PRNewswire/ — The global anaplastic lymphoma kinase (ALK) inhibitors market by type (second-generation ALK inhibitors,…

NEW YORK, May 14, 2021 /PRNewswire/ — The global anaplastic lymphoma kinase (ALK) inhibitors market by type (second-generation ALK inhibitors, first-generation ALK inhibitors, and third-generation ALK inhibitors) and geography (North America, Europe, Asia, and ROW) has been added to Technavio’s offering. The global anaplastic lymphoma kinase (ALK) inhibitors market is expected to grow by USD 3.43 billion, at a CAGR of almost 22% during 2021-2025.

Request a Free Sample Report to Know More

The market witnessed a slight decline in the sales of ALK inhibitors in 2020 as several scheduled treatments were either delayed or postponed. Besides, the high incidence of COVID-19 in the second wave has limited the movement of people, which has disrupted the supply chain and logistic operations. These factors are expected to hinder the growth of the ALK inhibitors market to some extent during the forecast period.

The market is expected to be driven by factors such as the high target affinity and specificity of ALK inhibitors, the high prevalence of lung cancer, and the presence of patient assistance programs.

The report also offers information on the upcoming trends and challenges that will influence market growth.

Download Our Free Sample Report

Anaplastic Lymphoma Kinase (ALK) Inhibitors Market: Opportunities

The rising consumption of tobacco and the passive inhalation of poisonous gases have increased the prevalence of lung disorders globally. In addition, the growing prevalence of cancer, including NSCLC, and the increasing need for promising therapeutics are driving the demand for ALK inhibitors. Besides, the increasing awareness about ALK inhibitors among patients and the wide availability of different ALK inhibitors are expected to provide several growth opportunities in the global anaplastic lymphoma kinase inhibitors market during the forecast period.

Anaplastic Lymphoma Kinase (ALK) Inhibitors Market: Segmentation by Type

Based on the segmentation by type, the market generated maximum revenue in the second-generation ALK inhibitors segment in 2020. The segment is driven by the increasing regulatory approvals of second-generation ALK inhibitors. Also, the rising prevalence of cancer is expected to fuel the growth of the segment during the forecast period.

Anaplastic Lymphoma Kinase (ALK) Inhibitors Market: Segmentation by Geography

North America held the largest market share in 2020 and the market growth in the region is expected to be faster compared to the growth of the market in other regions. The growth of the market in North America can be attributed to the high sales of approved ALK inhibitors and the increasing prevalence of lung cancer. In addition, an increase in R&D spending by vendors is expected to contribute to the growth of the ALK inhibitors market in North America during the forecast period.

One of the fortune 500 companies had used the detailed research report on the anaplastic lymphoma kinase (ALK) inhibitors market and had decided to increase their market share in the North American region which offers the highest market opportunities during the forecast period.

Explore more about market opportunities: Enquire about the report before purchasing

Anaplastic Lymphoma Kinase (ALK) Inhibitors Market: Major Vendors

Betta Pharmaceuticals Co. Ltd.

The company is involved in developing X-396. This molecule is under clinical phase II evaluated as an ALK inhibitor for lung cancer.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd.

The company sponsored the study on TQ-B3139, which is a competitive multi-target protein kinase inhibitor of Met/ALK/ROS.

F. Hoffmann-La Roche Ltd.

The company caters ALECENSA, which is indicated for the treatment of patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test.

Helsinn Healthcare SA

The company through a co-promotion agreement with Novartis for Zykadia provides detailing services for Zykadia in the US. Zykadia is an approved treatment for patients with metastatic NSCLC whose tumors are ALK-positive.

Takeda Pharmaceutical Co. Ltd.

The company provides ALUNBRIG (brigatinib), which is a prescription medicine used to treat people with NSCLC. It blocks certain proteins made by the ALK gene.

Along with the market data, Technavio offers customizations as per the specific needs of companies. The following customization options are available for the anaplastic lymphoma kinase (ALK) inhibitors market report: 

 Regional Analysis 

  •  Further breakdown of the market segmentation at requested regions. 

 Market Player Information 

  • Detailed analysis and profiling of additional market players, vendor segmentation, and vendor offerings.
  • Know the strategies adopted by vendors during the COVID-19 Recovery Phase.

Speak to our Analyst for a Customized Report

Related Reports on Anaplastic Lymphoma Kinase (ALK) Inhibitors Market:

Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market – Global selective serotonin reuptake inhibitors (SSRIs) market is segmented by application (depression, anxiety and panic disorder, and other mental conditions) and geography (North America, Europe, Asia, and ROW).

Download Exclusive Free Sample Report

Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market – Global PARP (poly adp-ribose polymerase) inhibitors market is segmented by end-user (ovarian cancer, breast cancer, and others) and geography (North America, Europe, APAC, South America, and MEA).

Download Exclusive Free Sample Report

Executive Summary

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 – 2025

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Type

  • Market segments
  • Comparison by Type
  • Second-generation ALK inhibitors – Market size and forecast 2020-2025
  • First-generation ALK inhibitors – Market size and forecast 2020-2025
  • Third-generation ALK inhibitors – Market size and forecast 2020-2025
  • Market opportunity by Type

Customer Landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America – Market size and forecast 2020-2025
  • Europe – Market size and forecast 2020-2025
  • Asia – Market size and forecast 2020-2025
  • ROW – Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity by geography
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Betta Pharmaceuticals Co. Ltd.
  • Bio-Techne Corp.
  • Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Helsinn Healthcare SA
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.
  • Turning Point Therapeutics Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: media@technavio.com

Website: www.technavio.com

Report: www.technavio.com/report/anaplastic-lymphoma-kinase-alk-inhibitors-market-industry-analysis

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/-3-43-billion-growth-expected-in-anaplastic-lymphoma-kinase-alk-inhibitors-market–20-14-yoy-growth-in-2021-amid-covid-19-spread–north-america-to-notice-maximum-growth–technavio-301291552.html

SOURCE Technavio